On June 27th, a group of 10 led by Zhou Hanmin, the Vice Chairman of Shanghai CPPCC came to Fosun Pharma Cloning Hi-Tech Park, visited Henlius lab, Fosun Pharma and its subsidiaries, and held a research seminar with Chen Qiyu, the Chairman of Fosun Pharma and other related personnel.

In Henlius lab at the macromolecular biological drug project base of Fosun Pharma, Zhou Hanmin and his team listened to the product introduction and R&D innovation status of Henlius under the guidance of Dr. Liu Shigao. During the bilateral exchange and discussion, Chen Qiyu, the Chairman of Fosun Pharma briefly introduced the current situation and talked about future development and Fosun Pharma’s contribution to Shanghai.

Zhou Hanmin vividly described the visit as "Three Goings" activity, i.e. going among the committee members, going into the committee member’s career, and going into career achievements and confusions that the member encountered. He said that Fosun is a private enterprise which has good image, reputation and strength over the world. Speaking of Expo 2010, Fosun Pharma’s active participation and great support deeply impressed Zhou who was the deputy director of the Executive Committee of the Shanghai World Expo, and he extended great gratitude.

After the visit, Zhou Hanmin thought highly of the development of Fosun Pharma, and proposed his ardent expectation. He said, first of all, Fosun Pharma has a high passion for innovation, which is all the incentive to work. Innovation is the ultimate goal while imitation is one of the paths. In the field of medicine, we should choose the right path to innovation, we hope Fosun Pharma can explore and summarize the successful practices and experience for the innovation-driven restructuring and development of Shanghai; secondly, Fosun Pharma has pharmaceutical manufacturing, medical device, medical service and other business sectors. We hope Fosun Pharma seize the opportunity and actively conduct international integration to achieve leapfrog development; thirdly, in the integration and acquisition, Fosun Pharma should contribute not only "capitals" but also "wisdom" to share its successful experience, and make plans for the integration objects; finally, the development of Fosun Pharma has some referential significance. We hope Fosun Pharma coordinate the development step by step, and ultimately achieve a breakthrough. In China's pharmaceutical and healthcare industry, we hope Fosun Pharma actively research and innovate with China's common, serious diseases to benefit Chinese people by blockbuster products. CPPCC will also try every effort to promote the development of Fosun Pharma, and discover outstanding research and innovation enterprises for the development of Shanghai.